Vifor Drops CV Endpoints In Phase IIIb Veltassa Study After COVID-19 Impacts

Ex-GSK Abbas Hussain Appointed CEO

Vifor Pharma is still hoping for further clinical data to help differentiate its potassium binder Veltassa in the competitive hyperkalemia market after recruitment into its Phase IIIb DIAMOND study was slowed by COVID-19-related changes to clinical practice, necessitating a new primary endpoint.  

St Gallen, Switzerland
St Gallen, Switzerland, Where Vifor Pharma Is Based • Source: Alamy

COVID-related revisions to a high-profile Veltassa Phase IIIb trial, and the appointment of a new CEO, ex-GSK executive Abbas Hussain, have punctuated the week at Switzerland’s specialty company, Vifor Pharma Group , which is aiming to build its presence in the cardio-renal space that is also being targeted by other companies. 

Vifor announced on 24 June that it was changing the primary endpoint in its much-anticipated Phase IIIb DIAMOND study involving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Roche, Following Sarepta, Pauses Elevidys Shipments In Certain Countries

 
• By 

Roche paused shipments of the Duchenne muscular dystrophy gene therapy in countries that reference US FDA approval of Elevidys after the agency asked Sarepta to pause US shipments; it remains available in Japan and Brazil.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.